Alzheimer Disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

Objective: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC).

Methods: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from ADNI. Common clinical markers, AD biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e. subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented.

Results: Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 individuals of these had follow-up data available. After 3.2±2.2 years 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher cerebrospinal fluid (CSF) tau levels.

Conclusion: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.